$RYAN

RYAN Maintained by Wells Fargo -- Price Target Lowered to $41.00

Wells Fargo maintained an 'Equal-Weight' rating for Ryan Specialty Holdings (RYAN) but lowered its price target to $41.00. The stock is currently trading at $37.12, with a GF Value™ of $82.86, suggesting a 55.2% undervaluation. The company has a GF Score™ of 78/100, indicating strong growth and profitability but concerns about valuation. Insider selling and mixed guru activity add to the cautious outlook.

Original reporting
Published Oct 12, 2026, 4:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 4:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$RYAN
Bearish
medium confidence
Mentioned
$RYAN
Relevance
6/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$RYANBearishMed
01

Why it matters

The target reduction reflects heightened caution amid sector uncertainty, potentially prompting sell‑side pressure.

02

Market read

The downgrade may cause modest downside for RYAN and could influence sentiment in the broader insurance niche.

03

What to watch

The company's strong growth scores and undervalued GF Value metric could support a rebound if fundamentals improve.

Relevance 6/10Novelty 6/10Timing: today

Background

Analyst rating updates often influence short‑term price action, especially when price targets are adjusted.

Company-level read

Ticker impact

$RYANBearishMedium confidence
Context

Wells Fargo lowered its price target for Ryan Specialty Holdings to $41, indicating a more cautious outlook.

Expected impact

likely downward pressure as investors price in the lower target

Evidence & confidence

A 4.65% target reduction signals caution and may prompt short‑term selling.

Market effects

The downgrade may weigh on the specialty insurance sector as peers are re‑evaluated.

U.S. and Canadian markets could see modest pressure on insurance stocks.

Limited to markets where Ryan Specialty Holdings is listed and traded.

Counterpoint

Some investors may view the target cut as an over‑reaction and see buying opportunity at current lows.

Key entities

  • Wells Fargo

    Provided the rating maintenance and price target reduction.

  • Ryan Specialty Holdings

    Subject of the analyst rating update.

Related articles

$RYANMedAI 8/10

Ryan Specialty posts Q2 revenue gain as E&S market slows

Ryan Specialty Holdings, Inc. reported second-quarter 2026 net commissions and fees of $902.7 million, up 7.4% year-over-year. Total revenue for the quarter reached $916.6 million, a 7.2% increase from $855.2 million a year earlier. Organic revenue growth came in at 6.7%, down from 7.1% in the prior-year period. The deceleration continues a trend across multiple quarters as the broader E&S market moderates.

$RYANMed

RYAN SPECIALTY REPORTS SECOND QUARTER 2026 RESULTS

RYAN SPECIALTY HOLDINGS, INC. (RYAN) filed an SEC Form 8-K — Results of Operations and Financial Condition. 1 RYAN SPECIALTY REPORTS SECOND QUARTER 2026 RESULTS - Total Revenue grew 7.2% year-over-year to $916.6 million - - Organic Revenue Growth Rate* of 6.7% year-over-year - - Net Income of $108.4 million , or $0.33 per diluted share - - Adjusted EBITDAC* grew 6.0% year-over-year to

$MRNAHigh

Moderna's melanoma vaccine succeeds in major trial. So why did its stock plunge?

Moderna and Merck's experimental melanoma vaccine, combined with Keytruda, reduced recurrence or death risk by 42% in a Phase 3 trial. Despite positive results, Moderna's shares fell 18%, likely due to high investor expectations. The vaccine is personalized using mRNA technology, targeting unique tumor mutations. Trial data showed 82.2% of patients treated with the vaccine and Keytruda were alive without recurrence after two years, compared to 70% with Keytruda alone.